Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.
about
Cross-regulation of TNF and IFN-alpha in autoimmune diseasesReplicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-responseInterferon alpha-induced lupus: proof of principleInterferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.Rheumatic disease following immunotherapy.Current methods for detecting antibodies against erythropoietin and other recombinant proteins.Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review.Essential thrombocythemia (ET): moving from palliation to cure.Regulation of early complement components C3 and C4 in the synoviumImmunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature.Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus.Therapy of ocular Behçet disease.Interferon-alpha in childhood haematological malignancies.Role of the biologics in autoimmunity.Cutaneous lymphocytic vasculopathy in lymphoproliferative disorders--a paraneoplastic lymphocytic vasculitis of the skin.Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritisLong term recombinant interferon alpha treatment in MS with special emphasis to side effects.The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update.Autoimmunity in hepatitis C and D virus infection.Lenalidomide-Associated ITP.Interferon-alpha drives T cell-mediated immunopathology in the intestine.Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy.Investigation of the ototoxic effects of interferon alpha2A on the mouse cochlea.Effects of interferon-alpha2b on hearing.Interferon-induced vitiligo in hepatitis C patients: a case series.The Clinical Significance of Autoantibodies in Hepatitis C Patients Submitted to Interferon Treatment.[Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology].Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis.Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemiaFênomeno de Raynaud grave associado a terapia com interferon-beta para esclerose múltipla: relato de caso
P2860
Q24556513-B69F65FE-0E53-4340-A167-9FBE1A3D4738Q27478215-4C0C6D62-E1AC-44AA-AF26-29763CFA02ABQ28282720-F00B85DA-71A1-416A-9B2D-6BF05FAF1FB9Q33544158-E77201C9-6282-47B9-A58B-38939312DED2Q33565321-53C0CB1A-107F-4A96-9F32-F6398305938CQ33593537-C292F7D2-AFB8-456E-98B2-D3809A6D9720Q33901227-1701C6F0-6AFA-40D6-80B3-C292AB8631CCQ33973488-66449ED0-550C-404C-8B4D-A3C6C722DEDAQ34737065-55FBFA68-0B90-44A5-B1FB-A252C2DFB650Q35022117-FB8872B7-7DFD-4D4F-BA59-28113C8D4583Q35225283-5A0CD442-2AF2-490A-92C2-0A66E0297070Q36371451-C6EAB9D0-5944-4DB6-BAAA-D545E5DF4D6CQ36951009-D38E19E8-923B-40BA-A105-413E98C08B48Q38174652-F32148A6-63EF-4680-81EC-57FB28360E74Q38646855-CC6962E5-10C3-4996-B8EB-30345CBBE87EQ40498828-E760B229-B6DC-4C9D-8E3F-9EE4EBD93DE4Q40548705-51E9FC6F-42D2-4156-AA50-D92E1A744F8CQ40622354-ECA69AD9-19DD-4721-BA03-E469945706F4Q40666166-C070A9D0-0871-451C-BA06-2B0F9D0BC05EQ40953190-333C2D0B-38C6-4ADA-B13C-00FDFA35A40FQ41115162-C426D7D2-3383-4EF0-826F-F6CF46C10B9DQ42278507-F1EBAD88-185E-4A22-9765-390147D8C17FQ43690829-4D18CE1B-3813-4F8E-B28F-134C4483C033Q45868754-7A990BFB-4EBA-4A31-B8A8-EDD949B5976EQ48966591-A467FEB5-103A-466A-9320-5EA4B4FBD853Q50475497-994BF1AE-7272-43AF-BAFD-23E7B33FA96CQ50559290-6ED14969-FDC2-4136-B037-6CCEE305DDBBQ51069229-48D92E93-0C1B-45A4-ADAA-32BF41BE1EE0Q52897774-EB8CE551-7F7B-49E2-8F2D-2F41B9EA4EC4Q53992563-0A65D6A5-CE0E-4253-BC9D-5DDF44AA4092Q56985898-4E263018-C9EE-4F97-8DF7-A59B9DDFD689Q57381831-DBAD8FBA-BFFC-42FA-854D-CAC5CEF91128
P2860
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.
description
1990 nî lūn-bûn
@nan
1990 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@ast
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@en
type
label
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@ast
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@en
prefLabel
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@ast
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@en
P2093
P1433
P1476
Exacerbation of symptoms of au ...... ving alpha-interferon therapy.
@en
P2093
P304
P356
10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5
P407
P577
1990-05-01T00:00:00Z